Pharmaceutical Contract Development and Manufacturing Market by Service (Pharmaceutical, Biologics, Active Pharma Ingredients, Tablet, Capsule, Parenteral, Oral Liquid), End User (Big Pharma, Small Pharma, Generic Pharma, CRO) - Global Forecast to 2024
“The global pharmaceutical contract development and manufacturing market is projected to grow at a CAGR of 7.1%.”
The pharmaceutical contract development and manufacturing market is expected to reach USD 126.6 billion by 2024 from an estimated USD 90.0 billion in 2019, at a CAGR of 7.1%. The rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs are the primary growth factors for this market. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are expected to offer significant growth opportunities for players in this market. However, the introduction of serialization and changing trade policies between countries are major market challenges.
“The biologics manufacturing segment is expected to grow at the highest rate during the forecast period.”
On the basis of service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. The biologics manufacturing segment is projected to witness the highest growth in the pharmaceutical contract development and manufacturing market during the forecast period. Growth in this segment is largely driven by the growing generics market and the impending patent cliff in the pharmaceuticals industry, which have propelled interest toward biologics.
“The big pharma end user segment is expected to account for the largest market share in 2019.”
The big pharma end-user segment holds the largest share of the pharmaceutical contract development and manufacturing market. The emergence of new medicines and therapy forms, pricing pressure, pipeline challenges, and growing opportunities in emerging markets are factors contributing to the larger share of this segment.
“The Asia Pacific is likely to be the fastest-growing market for players operating in the pharmaceutical contract development and manufacturing market.”
Although Europe accounted for the largest share of the global pharmaceutical contract development and manufacturing market in 2018, the Asia Pacific is expected to witness the highest CAGR during the forecast period. The growth of its manufacturing sector, favorable government regulations, expansions by leading companies, increasing emphasis on off-patent drugs, and its highly skilled workforce are factors driving the growth of this regional segment.
A breakdown of the primary participants referred to for this report is provided below:
Research Coverage:
This report analyzes the market for various pharmaceutical contract development and manufacturing services and their adoption patterns. It aims at estimating the market size and future growth potential of the global pharmaceutical contract development and manufacturing market and its service, end user, and regional segments. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, service offerings, and recent developments.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.
This report provides insights on the following pointers:
The pharmaceutical contract development and manufacturing market is expected to reach USD 126.6 billion by 2024 from an estimated USD 90.0 billion in 2019, at a CAGR of 7.1%. The rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs are the primary growth factors for this market. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are expected to offer significant growth opportunities for players in this market. However, the introduction of serialization and changing trade policies between countries are major market challenges.
“The biologics manufacturing segment is expected to grow at the highest rate during the forecast period.”
On the basis of service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. The biologics manufacturing segment is projected to witness the highest growth in the pharmaceutical contract development and manufacturing market during the forecast period. Growth in this segment is largely driven by the growing generics market and the impending patent cliff in the pharmaceuticals industry, which have propelled interest toward biologics.
“The big pharma end user segment is expected to account for the largest market share in 2019.”
The big pharma end-user segment holds the largest share of the pharmaceutical contract development and manufacturing market. The emergence of new medicines and therapy forms, pricing pressure, pipeline challenges, and growing opportunities in emerging markets are factors contributing to the larger share of this segment.
“The Asia Pacific is likely to be the fastest-growing market for players operating in the pharmaceutical contract development and manufacturing market.”
Although Europe accounted for the largest share of the global pharmaceutical contract development and manufacturing market in 2018, the Asia Pacific is expected to witness the highest CAGR during the forecast period. The growth of its manufacturing sector, favorable government regulations, expansions by leading companies, increasing emphasis on off-patent drugs, and its highly skilled workforce are factors driving the growth of this regional segment.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1 (21%), Tier 2 (26%), and Tier 3 (53%)
- By Designation: C-level (32%), Director-level (26%), and Others (42%)
- By Region: North America (35%), Europe (30%), Asia Pacific (15%), Latin America (10%), and the Middle East & Africa (10%)
Research Coverage:
This report analyzes the market for various pharmaceutical contract development and manufacturing services and their adoption patterns. It aims at estimating the market size and future growth potential of the global pharmaceutical contract development and manufacturing market and its service, end user, and regional segments. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, service offerings, and recent developments.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.
This report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the service portfolios offered by the top players in the global pharmaceutical contract development and manufacturing market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the global pharmaceutical contract development and manufacturing market
- Market Development: Comprehensive information on the lucrative emerging regions
- Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the global pharmaceutical contract development and manufacturing market
- Competitive Assessment: In-depth assessment of market ranking, growth strategies, revenue analysis, and services of leading players in the global pharmaceutical contract development and manufacturing market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key data from primary sources
2.1.2.2 Breakdown of primaries
2.1.2.3 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION APPROACH
2.4 MARKET PLAYERS RANKING ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING: MARKET OVERVIEW
4.2 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.3 REGIONAL MIX: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET (2019–2024)
4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEVELOPED VS. DEVELOPING MARKETS, 2019 VS. 2024
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing demand for generics
5.2.1.2 Increasing investments in pharmaceutical R&D
5.2.1.3 Investments in advanced manufacturing technologies by CDMOs
5.2.2 OPPORTUNITIES
5.2.2.1 Increasing demand for biological therapies
5.2.2.2 Growing focus on specialty medicines
5.2.2.3 Growth in the nuclear medicine sector
5.2.2.4 Growing demand for cell and gene therapies
5.2.3 CHALLENGES
5.2.3.1 Introduction of serialization
5.2.3.2 Changing trade policies between countries
5.2.4 TRENDS
5.2.4.1 Increasing CDMO manufacturing footprint in Asian countries
5.2.4.2 CDMO industry consolidation
5.2.4.3 Increasing outsourcing of clinical trials to emerging markets
6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE
6.1 INTRODUCTION
6.2 PHARMACEUTICAL MANUFACTURING SERVICES
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
6.2.1.1 Need to cut costs and ensure focus on core areas leads companies to outsource API manufacturing
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
6.2.2.1 Parenteral/injectable manufacturing services
6.2.2.1.1 Need for high levels of expertise and growing drug development activity are driving the demand for contract manufacturing
6.2.2.2 Tablet manufacturing services
6.2.2.2.1 Shifting manufacturing requirements and need to streamline production processes is driving market growth
6.2.2.3 Capsule manufacturing services
6.2.2.3.1 Growth in demand for capsule formulations has ensured growth opportunities for service providers
6.2.2.4 Oral liquid manufacturing services
6.2.2.4.1 Complexities involved in oral liquid manufacturing have prompted companies to look to outsourcing
6.2.2.5 Other formulations
6.3 DRUG DEVELOPMENT SERVICES
6.3.1 DRUG SUBSTANCE COMPLEXITY AND HIGH COSTS HAVE SUPPORTED THE OUTSOURCING OF DRUG DEVELOPMENT
6.4 BIOLOGICS MANUFACTURING SERVICES
6.4.1 BIOLOGICS API MANUFACTURING SERVICES
6.4.1.1 The market for biologics API manufacturing is still in the emergent phase
6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
6.4.2.1 Increasing R&D costs and process complexity have prompted the shift toward contract manufacturing
7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER
7.1 INTRODUCTION
7.2 BIG PHARMA
7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPY FORMS TO CONTRIBUTE TO THE GROWTH OF THIS MARKET
7.3 SMALL & MID-SIZE PHARMA
7.3.1 GROWING DEVELOPMENT OF BIOLOGIC DRUGS AND HIGH PRICING PRESSURE TO BOOST MARKET GROWTH
7.4 GENERIC PHARMACEUTICAL COMPANIES
7.4.1 GROWING DEMAND FOR GENERICS TO SUPPORT MARKET GROWTH
7.5 OTHER END USERS
8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION
8.1 INTRODUCTION
8.2 EUROPE
8.2.1 ITALY
8.2.1.1 Increasing focus on clinical research and the growing popularity of branded drugs are driving the demand for contract development and manufacturing
8.2.2 GERMANY
8.2.2.1 High healthcare expenditure and increased pharmaceutical production to support market growth
8.2.3 FRANCE
8.2.3.1 Presence of leading pharmaceutical companies to support market growth in France
8.2.4 UK
8.2.4.1 Growth in the generics market and the rising cost of manufacturing parenteral formulations are driving market growth
8.2.5 SWITZERLAND
8.2.5.1 Large volume of pharmaceutical production and growing scope for generics is expected to growth opportunities
8.2.6 SPAIN
8.2.6.1 Increase in biologics production to support market growth
8.2.7 REST OF EUROPE
8.3 NORTH AMERICA
8.3.1 US
8.3.1.1 The US dominates the North American pharmaceutical contract development and manufacturing market
8.3.2 CANADA
8.3.2.1 Growth of the emerging markets and slowdown in new product approvals will hamper market growth
8.4 ASIA PACIFIC
8.4.1 INDIA
8.4.1.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India
8.4.2 CHINA
8.4.2.1 Favorable government regulations are fueling market growth in China
8.4.3 JAPAN
8.4.3.1 Growing generics demand and push from the government will drive the demand for contract manufacturing of drugs
8.4.4 REST OF ASIA PACIFIC
8.5 LATIN AMERICA
8.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM
8.6 MIDDLE EAST & AFRICA
8.6.1 GOVERNMENT SUPPORT TO BOOST LOCAL PRODUCTION IS EXPECTED TO OFFER GROWTH OPPORTUNITIES FOR THE CONTRACT MANUFACTURERS IN THE REGION
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 MARKET RANKING
9.2.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY KEY PLAYERS, 2018
9.3 COMPETITIVE LEADERSHIP MAPPING
9.3.1 VISIONARY LEADERS
9.3.2 INNOVATORS
9.3.3 DYNAMIC DIFFERENTIATORS
9.3.4 EMERGING COMPANIES
9.4 COMPETITIVE SITUATION AND TRENDS
9.4.1 PRODUCT LAUNCHES
9.4.2 EXPANSIONS
9.4.3 ACQUISITIONS
9.4.4 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
10 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
10.1 THERMO FISHER SCIENTIFIC INC.
10.2 CATALENT, INC.
10.3 LONZA GROUP LTD
10.4 RECIPHARM AB
10.5 VETTER PHARMA INTERNATIONAL GMBH
10.6 FAMAR HEALTH CARE SERVICES
10.7 ABBVIE INC.
10.8 AENOVA GROUP
10.9 CONSORT MEDICAL PLC
10.10 ALMAC GROUP
10.11 SIEGFRIED HOLDING AG
10.12 EVONIK INDUSTRIES AG
10.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
11 APPENDIX
11.1 INSIGHTS OF INDUSTRY EXPERTS
11.2 DISCUSSION GUIDE
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.4 AVAILABLE CUSTOMIZATIONS
11.5 RELATED REPORTS
11.6 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key data from primary sources
2.1.2.2 Breakdown of primaries
2.1.2.3 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION APPROACH
2.4 MARKET PLAYERS RANKING ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING: MARKET OVERVIEW
4.2 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.3 REGIONAL MIX: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET (2019–2024)
4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEVELOPED VS. DEVELOPING MARKETS, 2019 VS. 2024
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing demand for generics
5.2.1.2 Increasing investments in pharmaceutical R&D
5.2.1.3 Investments in advanced manufacturing technologies by CDMOs
5.2.2 OPPORTUNITIES
5.2.2.1 Increasing demand for biological therapies
5.2.2.2 Growing focus on specialty medicines
5.2.2.3 Growth in the nuclear medicine sector
5.2.2.4 Growing demand for cell and gene therapies
5.2.3 CHALLENGES
5.2.3.1 Introduction of serialization
5.2.3.2 Changing trade policies between countries
5.2.4 TRENDS
5.2.4.1 Increasing CDMO manufacturing footprint in Asian countries
5.2.4.2 CDMO industry consolidation
5.2.4.3 Increasing outsourcing of clinical trials to emerging markets
6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE
6.1 INTRODUCTION
6.2 PHARMACEUTICAL MANUFACTURING SERVICES
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
6.2.1.1 Need to cut costs and ensure focus on core areas leads companies to outsource API manufacturing
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
6.2.2.1 Parenteral/injectable manufacturing services
6.2.2.1.1 Need for high levels of expertise and growing drug development activity are driving the demand for contract manufacturing
6.2.2.2 Tablet manufacturing services
6.2.2.2.1 Shifting manufacturing requirements and need to streamline production processes is driving market growth
6.2.2.3 Capsule manufacturing services
6.2.2.3.1 Growth in demand for capsule formulations has ensured growth opportunities for service providers
6.2.2.4 Oral liquid manufacturing services
6.2.2.4.1 Complexities involved in oral liquid manufacturing have prompted companies to look to outsourcing
6.2.2.5 Other formulations
6.3 DRUG DEVELOPMENT SERVICES
6.3.1 DRUG SUBSTANCE COMPLEXITY AND HIGH COSTS HAVE SUPPORTED THE OUTSOURCING OF DRUG DEVELOPMENT
6.4 BIOLOGICS MANUFACTURING SERVICES
6.4.1 BIOLOGICS API MANUFACTURING SERVICES
6.4.1.1 The market for biologics API manufacturing is still in the emergent phase
6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
6.4.2.1 Increasing R&D costs and process complexity have prompted the shift toward contract manufacturing
7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER
7.1 INTRODUCTION
7.2 BIG PHARMA
7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPY FORMS TO CONTRIBUTE TO THE GROWTH OF THIS MARKET
7.3 SMALL & MID-SIZE PHARMA
7.3.1 GROWING DEVELOPMENT OF BIOLOGIC DRUGS AND HIGH PRICING PRESSURE TO BOOST MARKET GROWTH
7.4 GENERIC PHARMACEUTICAL COMPANIES
7.4.1 GROWING DEMAND FOR GENERICS TO SUPPORT MARKET GROWTH
7.5 OTHER END USERS
8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION
8.1 INTRODUCTION
8.2 EUROPE
8.2.1 ITALY
8.2.1.1 Increasing focus on clinical research and the growing popularity of branded drugs are driving the demand for contract development and manufacturing
8.2.2 GERMANY
8.2.2.1 High healthcare expenditure and increased pharmaceutical production to support market growth
8.2.3 FRANCE
8.2.3.1 Presence of leading pharmaceutical companies to support market growth in France
8.2.4 UK
8.2.4.1 Growth in the generics market and the rising cost of manufacturing parenteral formulations are driving market growth
8.2.5 SWITZERLAND
8.2.5.1 Large volume of pharmaceutical production and growing scope for generics is expected to growth opportunities
8.2.6 SPAIN
8.2.6.1 Increase in biologics production to support market growth
8.2.7 REST OF EUROPE
8.3 NORTH AMERICA
8.3.1 US
8.3.1.1 The US dominates the North American pharmaceutical contract development and manufacturing market
8.3.2 CANADA
8.3.2.1 Growth of the emerging markets and slowdown in new product approvals will hamper market growth
8.4 ASIA PACIFIC
8.4.1 INDIA
8.4.1.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India
8.4.2 CHINA
8.4.2.1 Favorable government regulations are fueling market growth in China
8.4.3 JAPAN
8.4.3.1 Growing generics demand and push from the government will drive the demand for contract manufacturing of drugs
8.4.4 REST OF ASIA PACIFIC
8.5 LATIN AMERICA
8.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM
8.6 MIDDLE EAST & AFRICA
8.6.1 GOVERNMENT SUPPORT TO BOOST LOCAL PRODUCTION IS EXPECTED TO OFFER GROWTH OPPORTUNITIES FOR THE CONTRACT MANUFACTURERS IN THE REGION
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 MARKET RANKING
9.2.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY KEY PLAYERS, 2018
9.3 COMPETITIVE LEADERSHIP MAPPING
9.3.1 VISIONARY LEADERS
9.3.2 INNOVATORS
9.3.3 DYNAMIC DIFFERENTIATORS
9.3.4 EMERGING COMPANIES
9.4 COMPETITIVE SITUATION AND TRENDS
9.4.1 PRODUCT LAUNCHES
9.4.2 EXPANSIONS
9.4.3 ACQUISITIONS
9.4.4 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
10 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
10.1 THERMO FISHER SCIENTIFIC INC.
10.2 CATALENT, INC.
10.3 LONZA GROUP LTD
10.4 RECIPHARM AB
10.5 VETTER PHARMA INTERNATIONAL GMBH
10.6 FAMAR HEALTH CARE SERVICES
10.7 ABBVIE INC.
10.8 AENOVA GROUP
10.9 CONSORT MEDICAL PLC
10.10 ALMAC GROUP
10.11 SIEGFRIED HOLDING AG
10.12 EVONIK INDUSTRIES AG
10.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
11 APPENDIX
11.1 INSIGHTS OF INDUSTRY EXPERTS
11.2 DISCUSSION GUIDE
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.4 AVAILABLE CUSTOMIZATIONS
11.5 RELATED REPORTS
11.6 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 2 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 3 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 4 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 5 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 6 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 7 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 8 TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 9 CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 10 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 11 OTHER FORMULATION MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 12 DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 13 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 14 BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 15 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 16 BIOLOGICS FINISHED DOSAGE FORMULATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 17 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 18 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 19 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MID-SIZE PHARMA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 20 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 23 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 24 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 25 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 26 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 27 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 28 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 29 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 30 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 31 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 32 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 33 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 34 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 35 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 36 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 37 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 38 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 39 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 40 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 41 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 42 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 43 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 44 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 45 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 46 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 47 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 48 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 49 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 50 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 51 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 52 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 53 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 54 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 55 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 56 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 57 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 58 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 59 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 60 ROE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 61 ROE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 62 ROE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 63 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 64 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 65 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 66 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 67 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 68 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 69 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 70 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 71 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 72 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 73 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 74 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 75 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 76 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 77 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 78 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 79 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 80 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 81 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 82 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 83 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 84 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 85 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 86 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 87 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 88 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 89 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 90 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 91 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 92 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 93 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 94 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 95 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 96 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 97 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 98 JAPAN: FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 99 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 100 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 101 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 102 ROAPAC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 103 ROAPAC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 104 ROAPAC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 105 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 106 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 107 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 108 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 109 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 110 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 111 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 112 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 113 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 114 MIDDLE EAST & AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 115 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 116 PRODUCT LAUNCHES, 2016–2019
TABLE 117 EXPANSIONS, 2016–2019
TABLE 118 ACQUISITIONS, 2016–2019
TABLE 119 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 2016–2019
TABLE 1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 2 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 3 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 4 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 5 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 6 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 7 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 8 TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 9 CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 10 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 11 OTHER FORMULATION MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 12 DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 13 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 14 BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 15 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 16 BIOLOGICS FINISHED DOSAGE FORMULATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 17 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 18 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 19 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MID-SIZE PHARMA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 20 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 23 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 24 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 25 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 26 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 27 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 28 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 29 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 30 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 31 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 32 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 33 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 34 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 35 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 36 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 37 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 38 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 39 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 40 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 41 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 42 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 43 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 44 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 45 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 46 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 47 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 48 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 49 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 50 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 51 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 52 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 53 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 54 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 55 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 56 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 57 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 58 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 59 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 60 ROE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 61 ROE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 62 ROE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 63 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 64 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 65 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 66 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 67 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 68 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 69 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 70 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 71 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 72 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 73 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 74 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 75 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 76 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 77 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 78 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 79 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 80 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 81 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 82 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 83 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 84 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 85 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 86 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 87 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 88 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 89 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 90 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 91 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 92 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 93 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 94 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 95 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 96 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 97 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 98 JAPAN: FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 99 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 100 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 101 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 102 ROAPAC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 103 ROAPAC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 104 ROAPAC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 105 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 106 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 107 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 108 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 109 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 110 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 111 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION)
TABLE 112 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 113 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 114 MIDDLE EAST & AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 115 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 116 PRODUCT LAUNCHES, 2016–2019
TABLE 117 EXPANSIONS, 2016–2019
TABLE 118 ACQUISITIONS, 2016–2019
TABLE 119 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 2016–2019
LIST OF FIGURES
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS, AND REGION
FIGURE 3 BOTTOM-UP APPROACH
FIGURE 4 TOP-DOWN APPROACH
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2019 VS. 2024 (USD BILLION)
FIGURE 7 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2019 VS. 2024 (USD BILLION)
FIGURE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2019 VS. 2024 (USD BILLION)
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
FIGURE 10 GROWING DEMAND FOR GENERICS IS ONE OF THE KEY FACTORS DRIVING MARKET GROWTH
FIGURE 11 INDIA IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 12 ASIA PACIFIC TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD (2019–2024)
FIGURE 13 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN 2019 & 2024
FIGURE 14 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS
FIGURE 15 GROWTH OF THE GENERICS MARKET (2006 VS. 2016)
FIGURE 16 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2017)
FIGURE 17 GLOBAL LIFE SCIENCE R&D SPENDING (2016–2018)
FIGURE 18 CDMO MERGER AND ACQUISITION VOLUME AND VALUE (2012–2016)
FIGURE 19 TOP CONSOLIDATORS (2012–2018)
FIGURE 20 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT TO DOMINATE THE SERVICES MARKET DURING THE FORECAST PERIOD
FIGURE 21 BIG PHARMA FORMED THE LARGEST END USER SEGMENT IN THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
FIGURE 22 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 23 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
FIGURE 24 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
FIGURE 25 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
FIGURE 26 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM JANUARY 2016 TO JULY 2019
FIGURE 27 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET RANKING, BY KEY PLAYER, 2018
FIGURE 28 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: (GLOBAL) COMPETITIVE LEADERSHIP MAPPING (2018)
FIGURE 29 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2018)
FIGURE 30 CATALENT, INC.: COMPANY SNAPSHOT (2018)
FIGURE 31 LONZA GROUP LTD: COMPANY SNAPSHOT (2018)
FIGURE 32 RECIPHARM AB: COMPANY SNAPSHOT (2018)
FIGURE 33 ABBVIE INC.: COMPANY SNAPSHOT (2018)
FIGURE 34 CONSORT MEDICAL PLC: COMPANY SNAPSHOT (2018)
FIGURE 35 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2018)
FIGURE 36 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2018)
FIGURE 37 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2018)
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS, AND REGION
FIGURE 3 BOTTOM-UP APPROACH
FIGURE 4 TOP-DOWN APPROACH
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2019 VS. 2024 (USD BILLION)
FIGURE 7 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2019 VS. 2024 (USD BILLION)
FIGURE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2019 VS. 2024 (USD BILLION)
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
FIGURE 10 GROWING DEMAND FOR GENERICS IS ONE OF THE KEY FACTORS DRIVING MARKET GROWTH
FIGURE 11 INDIA IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 12 ASIA PACIFIC TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD (2019–2024)
FIGURE 13 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN 2019 & 2024
FIGURE 14 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS
FIGURE 15 GROWTH OF THE GENERICS MARKET (2006 VS. 2016)
FIGURE 16 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2017)
FIGURE 17 GLOBAL LIFE SCIENCE R&D SPENDING (2016–2018)
FIGURE 18 CDMO MERGER AND ACQUISITION VOLUME AND VALUE (2012–2016)
FIGURE 19 TOP CONSOLIDATORS (2012–2018)
FIGURE 20 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT TO DOMINATE THE SERVICES MARKET DURING THE FORECAST PERIOD
FIGURE 21 BIG PHARMA FORMED THE LARGEST END USER SEGMENT IN THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
FIGURE 22 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 23 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
FIGURE 24 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
FIGURE 25 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
FIGURE 26 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM JANUARY 2016 TO JULY 2019
FIGURE 27 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET RANKING, BY KEY PLAYER, 2018
FIGURE 28 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: (GLOBAL) COMPETITIVE LEADERSHIP MAPPING (2018)
FIGURE 29 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2018)
FIGURE 30 CATALENT, INC.: COMPANY SNAPSHOT (2018)
FIGURE 31 LONZA GROUP LTD: COMPANY SNAPSHOT (2018)
FIGURE 32 RECIPHARM AB: COMPANY SNAPSHOT (2018)
FIGURE 33 ABBVIE INC.: COMPANY SNAPSHOT (2018)
FIGURE 34 CONSORT MEDICAL PLC: COMPANY SNAPSHOT (2018)
FIGURE 35 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2018)
FIGURE 36 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2018)
FIGURE 37 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2018)
